Prime Medicine (PRME) Profit After Tax (2021 - 2026)
Prime Medicine's (PRME) quarterly Profit After Tax came in at -$49.2 million in Q1 2026, up 5.2% YoY from -$46.8 million in Q1 2025, and down 6.97% on a QoQ basis from -$46.0 million in Q4 2025.
Prime Medicine (PRME) Profit After Tax (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Profit After Tax data on file, last reported at -$49.2 million in Q1 2026.
- Quarterly Profit After Tax rose 5.2% year-over-year to -$49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.4 million (up 1.81% YoY) and the FY2025 annual result came in at -$201.1 million, down 2.64% from the prior year.
- Profit After Tax declined to -$49.2 million in Q1 2026, from -$46.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$23.8 million in Q1 2022 to a low of -$65.5 million in Q4 2023.
- A 5-year average of -$46.2 million and a median of -$49.2 million in 2026 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax sank 78.83% — and 2024, when it soared 35.47%.
- Tracing PRME's Profit After Tax over 5 years: stood at -$59.5 million in 2022, then fell by 10.14% to -$65.5 million in 2023, then jumped by 35.47% to -$42.3 million in 2024, then decreased by 8.8% to -$46.0 million in 2025, then decreased by 6.97% to -$49.2 million in 2026.
- The last three Profit After Tax figures came in at -$49.2 million (Q1 2026), -$46.0 million (Q4 2025), and -$50.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | -42.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.12 Mn |
| Mar 31, 2026 | -49.21 Mn |
| Dec 31, 2025 | -46.00 Mn |
| Sep 30, 2025 | -50.58 Mn |
| Jun 30, 2025 | -52.59 Mn |
| Mar 31, 2025 | -51.91 Mn |
| Dec 31, 2024 | -42.28 Mn |
| Sep 30, 2024 | -52.52 Mn |
| Jun 30, 2024 | -55.33 Mn |
| Mar 31, 2024 | -45.76 Mn |
| Dec 31, 2023 | -65.51 Mn |
| Sep 30, 2023 | -50.59 Mn |
| Jun 30, 2023 | -42.39 Mn |
| Mar 31, 2023 | -39.40 Mn |
| Dec 31, 2022 | -59.48 Mn |
| Sep 30, 2022 | -29.35 Mn |
| Jun 30, 2022 | -29.35 Mn |
| Mar 31, 2022 | -23.84 Mn |
| Dec 31, 2021 | -50.55 Mn |
| Sep 30, 2021 | -16.41 Mn |